GT Biopharma Doses First GTB-5550 Patient, Intensifying B7-H3 Race with GSK
GT Biopharma dosed first patient on May 14 in its Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, with $9M cash runway through Q4 2026 and updates expected in 2H 2026. GSK’s B7-H3 ADC faces competition from this subcutaneously dosed TriKE in the $362B solid tumor market.
1. Phase 1 Trial Launch
On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 dose-escalation basket trial of GTB-5550, marking the third clinic entry of its TriKE platform and the first to use subcutaneous administration. Enrollment prioritizes advanced prostate, ovarian and pancreatic cancer patients who have failed prior therapies.
2. Heightened B7-H3 Competition
The B7-H3 antigen has emerged as a key oncology target with estimated $362 billion global solid tumor market potential. GSK’s antibody-drug conjugate program now faces direct competition from GT Biopharma’s subcutaneously dosed natural killer cell engager in the same antigen space.
3. Financial Position and Catalysts
As of March 31, 2026, GT Biopharma held approximately $9 million in cash, providing runway through Q4 2026. Investors can anticipate Phase 1 dose-escalation updates in the second half of 2026 as the trial progresses.
4. TriKE Platform Advantages
GTB-5550 is built on the second-generation TriKE architecture combining anti-CD16 and anti-B7-H3 nanobodies with wildtype IL-15, reported to be 10–40 times more potent than first-generation molecules. This design aims to enhance NK cell activation and survival with patient-friendly dosing.